Stockreport

Exelixis launches late-stage study of cabozantinib combo in prostate cancer [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF Exelixis (EXEL+2.2%initiatesCONTACT-02OTCQX:RHHBY-1.2%The primary endpoints of the 580-subject study are progression-free survival and overall survival.The estimated pri [Read more]